Price Fluctuations in Securities and Investment Securities and Valuation Losses
First written in FY2016. 9 of 30 entries say "Worsened", first in FY2017-Q2. Latest entry: FY2026.
Cresco moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2019: 54 of 136 companies on the "Worse" side.
59 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「In addition to the above, in the management of funds, the Company recorded a ¥641 million gain on sale of investment securities (extraordinary income) and a ¥54 million gain on redemption of investment securities (extraordinary income).」
While gains on the sale and redemption of investment securities arose, the Company also recorded a ¥15.324 million loss on valuation of investment securities, with gains and losses on valuation in financial-market-related activities coexisting. - FY2026-H1RestatedAnnual report
「In addition to the above, in the management of funds, the Company recorded a ¥262 million gain on sale of investment securities (extraordinary income) and a ¥54 million gain on redemption of investment securities (extraordinary income). Loss on valuation of investment securities 15,324」
While gains on the sale and redemption of investment securities arose, a ¥15.324 million loss on valuation was also recorded, and gains and losses on valuation of financial instruments continue to coexist. - FY2025-H1Gains and losses on valuation coexisted among financial instrumentsAnnual report
「In addition to the above, in the management of funds, the Company recorded a ¥30 million gain on valuation of derivatives, a ¥37 million gain on redemption of investment securities, a ¥21 million gain on sale of investment securities, and a ¥22 million loss on valuation of investment securities (extraordinary loss).」
In fund management, gains on valuation of derivatives and gains on redemption and sale of investment securities arose, while a loss on valuation of investment securities was also recorded, resulting in both gains and losses in financial-market-related activities. - FY2024RestatedAnnual report
「In addition, in connection with the management of funds, the Company recorded a ¥273 million gain on valuation of derivatives (non-operating income), a ¥323 million gain on sale of investment securities (extraordinary income), and a ¥108 million gain on redemption of investment securities (extraordinary income).」
Although gains on valuation, sales and redemptions arose in financial-market-related activities, the Company continues to disclose the market price fluctuation risk of financial instruments and the large scale of its fund management activities. - FY2024-Q2RestatedAnnual report
「In addition, in connection with the management of surplus funds, the Company recorded a ¥266 million gain on valuation of derivatives (non-operating income) and a ¥108 million gain on redemption of investment securities (extraordinary income).」
In financial-market-related activities, the Company recorded a ¥266 million gain on valuation of derivatives and a ¥108 million gain on redemption of investment securities, resulting in gains rather than valuation losses for the second consecutive quarter. - FY2024-Q1MitigatedAnnual report
「In addition, in connection with the management of surplus funds, the Company recorded a ¥282 million gain on valuation of derivatives (non-operating income) and a ¥108 million gain on redemption of investment securities (extraordinary income).」
The derivative valuation result changed from a loss recorded in the same period of the previous year to a ¥282 million gain in the current quarter, temporarily easing financial-market-related earnings and losses. - FY2023MaterialisedAnnual report
「In addition, during the consolidated fiscal year, the Company recorded a ¥226 million loss on valuation of derivatives and a ¥170 million loss on valuation of investment securities.」
Due to volatility in the financial markets, the Company recorded a ¥226 million loss on valuation of derivatives and a ¥170 million loss on valuation of investment securities. - FY2023-Q3WorsenedAnnual report
「However, in the management of funds, falling share prices in the United States, driven by interest rate hikes as an anti-inflation measure and concerns about the United States entering a recession, resulted in the recognition of a ¥789 million loss on valuation of derivatives (non-operating expense) relating to financial instruments held by the Company (yen-denominated bonds linked to the shares of other companies with early redemption provisions).」
Against a backdrop of falling U.S. share prices, the Company recorded a ¥789 million loss on valuation of derivatives, with financial-market-related risks carried over from the previous quarter becoming evident on a larger scale. - FY2023-Q2MitigatedAnnual report
「However, in its funds management activities, the company recognized a valuation loss on derivatives of ¥372 million, recorded as a non-operating expense, on the financial instrument it held, a yen-denominated bond linked to the shares of another company with an early-redemption provision, as US share prices declined amid concerns about a recession and interest-rate increases intended to contain inflation in the United States.」
Financial market-related risk continued to materialize, although the valuation loss declined from the ¥484 million reported for the previous quarter to ¥372 million on a cumulative basis for the current quarter. - FY2023-Q1WorsenedAnnual report
「However, in its funds management activities, the company recognized a valuation loss on derivatives of ¥484 million, recorded as a non-operating expense, on the financial instrument it held, a yen-denominated bond linked to the shares of another company with an early-redemption provision, as US share prices declined amid concerns about a recession and interest-rate increases intended to contain inflation in the United States.」
The company recognized a valuation loss on derivatives of ¥484 million on financial instruments it held due to the decline in US share prices, and the financial market-related risk that had been temporarily alleviated through the previous fiscal year re-emerged materially. - FY2022-Q2MitigatedAnnual report
「Valuation gain on derivatives ¥5.506 million」
During the six-month period ended the second quarter, the company recognized a valuation gain on derivatives and no valuation loss on investment securities. The valuation-loss risk that had emerged in the previous quarter was temporarily alleviated during the current quarter. - FY2022-Q1MaterialisedAnnual report
「Valuation loss on derivatives ¥4.487 million」
The company recognized a valuation loss on derivatives of ¥4.487 million during the first quarter, indicating that the risk of valuation losses arising from financial market fluctuations had materialized again, albeit on a small scale. - FY2021MitigatedAnnual report
「On the other hand, the implementation of large-scale fiscal stimulus measures worldwide to support economic recovery led to a rebound in share prices compared with the end of the previous consolidated fiscal year, resulting in the positive effect of an overall increase in the fair value of the financial instruments held by the Company.」
The recovery in share prices increased the fair value of financial instruments, and the company recognized a valuation gain on derivatives of ¥338.955 million during the fiscal year. The financial market-related losses that had emerged in the previous fiscal year were temporarily alleviated. - FY2021-Q3MitigatedAnnual report
「On the other hand, the implementation of large-scale fiscal stimulus measures worldwide to support economic recovery led to a rebound in share prices compared with the end of the previous consolidated fiscal year, resulting in the positive effect of an overall increase in the fair value of the financial instruments held by the Company.」
Following the recovery in share prices, the company recognized a valuation gain on derivatives of ¥395.717 million, while the valuation difference on other securities was a gain of ¥1,922.940 million. The financial market-related risk that had emerged at the end of the previous fiscal year was temporarily alleviated. - FY2021-Q2MitigatedAnnual report
「On the other hand, the implementation of large-scale fiscal stimulus measures worldwide to support economic recovery led to a rebound in share prices compared with the end of the previous consolidated fiscal year, resulting in the positive effect of an overall increase in the fair value of the financial instruments held by the Company.」
The rebound in share prices increased the fair value of financial instruments, and the company recognized, among other items, a valuation gain on derivatives of ¥276.093 million. The financial market-related risk that had emerged at the end of the previous fiscal year was temporarily alleviated during the quarter as well. - FY2021-Q1MitigatedAnnual report
「On the other hand, the implementation of large-scale fiscal stimulus measures worldwide to support economic recovery led to a rebound in share prices compared with the end of the previous consolidated fiscal year, resulting in the positive effect of an overall increase in the fair value of the financial instruments held by the Company.」
The rebound in share prices increased the fair value of financial instruments, and the company recognized a valuation gain on derivatives of ¥297.063 million and a valuation gain on securities of ¥12.298 million during the quarter. The valuation-loss risk that had emerged through the previous fiscal year was temporarily alleviated during the quarter. - FY2020WorsenedAnnual report
「Non-operating expenses increased by ¥395 million from the previous consolidated fiscal year to ¥469 million. This was mainly due to a ¥306 million increase in valuation losses on derivatives and a ¥24 million increase in valuation losses on securities following the worldwide decline in share prices caused by the COVID-19 pandemic, as well as the recognition of ¥23 million in expenses for the repurchase of treasury shares and ¥8 million in expenses for issuing stock acquisition rights.」
Against the backdrop of falling share prices caused by the COVID-19 pandemic, the company recognized a valuation loss on derivatives of ¥306 million, increasing losses related to financial markets. It also recognized a valuation loss on investment securities of ¥230.952 million and a loss on redemption of ¥194.447 million. - FY2020-Q3WorsenedAnnual report
「Valuation loss on investment securities ¥44.354 million ¥82.409 million Loss on redemption of investment securities — ¥194.447 million」
In addition to a valuation loss on investment securities of ¥82.409 million, the company recognized a loss on redemption of investment securities of ¥194.447 million, indicating that losses related to financial markets and securities continued to occur. - FY2020-Q2MaterialisedAnnual report
「During the six-month period ended the second quarter, the company recorded an impairment loss of ¥52.059 million on unlisted shares and other securities.」
The company recorded an impairment loss of ¥52.059 million on unlisted shares and other securities, indicating that the risk of valuation losses on securities continued to materialize. - FY2020-Q1WorsenedAnnual report
「Valuation loss on investment securities ¥53.583 million Valuation loss on derivatives ¥219.830 million」
The company recognized a valuation loss on investment securities of ¥53.583 million and a valuation loss on derivatives of ¥219.830 million during the first quarter, resulting in losses related to financial markets. - FY2019MitigatedAnnual report
「Extraordinary loss decreased by ¥53 million from the previous consolidated fiscal year to ¥358 million. This was mainly due to a ¥48 million increase in anniversary-related expenses, despite a ¥124 million decrease in the valuation loss on investment securities.」
Although the valuation loss on investment securities decreased from ¥235.288 million in the previous fiscal year to ¥111.225 million in the current fiscal year, valuation losses continued to occur and the risk had not been eliminated. - FY2019-Q3WorsenedAnnual report
「Valuation loss on investment securities ¥44.354 million」
The company recognized a valuation loss on investment securities of ¥44.354 million during the nine-month period ended the third quarter. The valuation difference on other securities also declined by ¥648.840 million, indicating that the realization of financial market risk continued. - FY2019-Q2MaterialisedAnnual report
「During the six-month period ended the second quarter, the company recorded an impairment loss of ¥6.453 million on unlisted shares and other securities.」
The risk of valuation losses on securities and investment securities materialized during the six-month period ended the second quarter as a ¥6.453 million impairment loss on unlisted shares and other securities. - FY2019-Q1MaterialisedAnnual report
「Valuation loss on investment securities ¥3.374 million」
The company also recognized a valuation loss on investment securities of ¥3.374 million during the first quarter, indicating that the risk of valuation losses due to financial market fluctuations continued to materialize. - FY2018WorsenedAnnual report
「During the consolidated fiscal year, the company recorded an impairment loss of ¥235.288 million on other securities.」
The impairment loss on securities increased from ¥100.499 million in the previous consolidated fiscal year to ¥235.288 million, indicating that the realization of financial market risk continued at a larger amount. - FY2018-Q3WorsenedAnnual report
「Valuation loss on investment securities ¥189.325 million」
The company recognized a valuation loss on investment securities of ¥189.325 million during the nine-month period ended the third quarter, indicating that the valuation-loss risk reported through the previous quarter continued to materialize at a larger amount. - FY2018-Q1MaterialisedAnnual report
「Valuation loss on investment securities ¥19.771 million」
The company recognized a valuation loss on investment securities of ¥19.771 million in the first quarter, indicating that the risk of valuation losses due to financial market fluctuations continued to materialize. - FY2017-Q2WorsenedAnnual report
「Valuation loss on securities ¥29.390 million」
The company recognized a valuation loss on securities of ¥29.390 million during the six-month period ended the second quarter. The total valuation difference on other securities was negative ¥259.090 million, indicating that deterioration in valuations due to financial market risk continued. - FY2017-Q1MaterialisedAnnual report
「Although the Group is working to minimize the risks associated with the valuation of securities and other investments it holds, their valuation depends on and is affected by trends in financial markets, including domestic and overseas economic conditions and equity markets, and could have a material impact on business performance.」
The company recognized a valuation loss on securities of ¥9.579 million during the quarter, while the valuation difference on other securities declined from negative ¥57.306 million at the end of the previous consolidated fiscal year to negative ¥254.286 million. - FY2016First statedAnnual report
「Share prices have been highly volatile in recent years, and declines in asset values could materially affect the Company's business performance and financial position.」
The company describes financial market risk and recognized an impairment loss on investment securities of ¥121.939 million and a valuation loss on securities of ¥37.866 million during the fiscal year. The valuation difference on other securities also shifted from a valuation gain of ¥509.766 million in the previous fiscal year to a valuation loss of ¥80.917 million in the current fiscal year.